CRH Medical (NYSEAMERICAN:CRHM) was upgraded by research analysts at Bloom Burton from an “accumulate” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.
Separately, Zacks Investment Research downgraded CRH Medical from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. One investment analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $3.25.
Shares of CRHM stock traded down $0.07 on Thursday, reaching $2.93. The company’s stock had a trading volume of 28,051 shares, compared to its average volume of 67,183. CRH Medical has a 12-month low of $2.51 and a 12-month high of $4.50.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.
See Also: Is it Safe to Invest in Commodities?
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.